Hormone therapy – oestrogen therapy in transwoman (male to female) and testosterone therapy in transman (female to male) — was associated with modifiable risk factors, such as HbA1c, cardiovascular markers, and vitamin D levels, according to Patricia Kapsner, MD, of the University of New Mexico, and colleagues.
“We known the metabolic effects of oestrogen and testosterone — the most frequent cross-sex hormone therapies used — from animal studies, as well as studies in the non-transgender populations,” she said during a press conference at the European Association for the Study of Diabetes meeting. However, there is a dearth of outcomes studies available among the transgender population with diabetes, she added.
